MiMedx Group Inc Common Stock (MDXG)

FairStock Score: 95/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $63 million in annual free cash flow (12.7% yield on market cap)
• High return on equity of 21.6% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.09, providing financial flexibility
• Altman Z-Score of 4.6 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 27.1% demonstrates strong top-line momentum

AI Analysis

MiMedx Group Inc Common Stock is a micro-cap healthcare company valued at $497 million. The business generates $419 million in annual revenue with a 3.6% net margin and $63 million in free cash flow. From a quality standpoint, MiMedx shows healthy Altman Z-Score of 4.6 and strong 22% ROE. On valuation, the stock is attractively valued at 10.5x earnings, with a modest 5% margin of safety vs Graham Number. Growth dynamics show revenue growing at 27.1% and profit growth of 104.2%. Our composite FairStock Score of 95/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

MiMedx's 27% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $63 million in annual free cash flow (12.7% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer